MedTrace Logo

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

NCT06123338 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2026-01-29

No results posted yet for this study

Summary

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Conditions

  • Esophageal Cancer
  • Gastric Adenocarcinoma
  • HER2 Gene Mutation

Interventions

DRUG

Pembrolizumab

Pembrolizumab will be administered on an every 3-week dosing schedule

DRUG

Trastuzumab

Trastuzumab will be administered on an every 3-week dosing schedule

DRUG

Oxaliplatin

Oxaliplatin every 3 weeks, +/-7 days

DRUG

Capecitabine

Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks

DRUG

5-Fluorouracil

5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks

DRUG

Docetaxel

Docetaxel administered intravenously once every 2 weeks.

Sponsors & Collaborators

Principal Investigators

  • Yelena Janjigian, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2027-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06123338 on ClinicalTrials.gov